Table 1.
Demographic and pre-biopsy clinical characteristics of men undergoing first prostate biopsy for prostate cancer detection in the EDRN analysis and PCPT validation cohorts, according to biopsy result.
| EDRN Analysis Cohort (N=635) | PCPT Validation Cohort (N=3833) | |||||
|---|---|---|---|---|---|---|
| No Prostate Cancer |
Indolent Prostate Cancer |
Histologically- aggressive Prostate Cancer |
No Prostate Cancer |
Indolent Prostate Cancer |
Histologically- aggressive Prostate Cancer |
|
| Number patients | 361 (57) | 88 (14) | 186 (29) | 3176 (83) | 333 (9) | 324 (8) |
| Age (years) * | 60 [54–66] | 61 [56–66] | 64 [59–71] | 69 [65–73] | 69 [65–73] | 69 [65–74] |
| BMI (kg/m2) | 27 [25–31] | 27 [25–31] | 27 [25–32] | 27 [25–30] | 27 [25–30] | 27 [25–30] |
| Non-Caucasian | 57 (16) | 13 (15) | 21 (11) | 86 (3) | 8 (2) | 19 (6) |
| Family history of prostate cancer |
88 (24) | 28 (32) | 60 (32) | 468 (15) | 67 (20) | 72 (22) |
| Abnormal DRE* | 57 (16) | 15 (17) | 59 (32) | 98 (3) | 57 (17) | 60 (15) |
| PSA (ng/mL) * | 4.6 [3.0–6.0] | 4.5 [3.4–6.0] | 6.6 [4.8–9.0] | 1.2 [0.7–2.0] | 1.8 [1.0–2.9] | 2.4 [1.5–4.0] |
| Prostate volume by TRUS (cc) * |
47 [35–65] | 44 [35–58] | 40 [31–55] | 34 [26–45] | 32 [25–42] | 33 [25–43] |
| PSA density (ng/mL/cc) * |
0.09 [0.06–0.12] | 0.10 [0.07–0.16] | 0.16 [0.10–0.25] | 0.03 [.02–.05] | 0.05 [0.03–0.09] | 0.07 [0.04–0.11] |
*
P<0.01 in univariate comparison of histologically-aggressive prostate cancer versus others; N(%) compared using Fisher’s exact tests; or median [interquartile range] compared using Kruskal-Wallis tests.
Abbreviations: BMI=body mass index; PSA=prostate specific antigen; TRUS=trans-rectal ultrasound; DRE=digital rectal exam